How do you pay?

How to pay the least

Lowest posted price

$55 a month

Jentadueto XR from Boehringer Ingelheim, without insurance.

  1. Sign up for Boehringer Ingelheim Direct self-pay.Sign up on boehringer-ingelheim.com 

No generic is sold yet.

Compare every option

Question
Brand nameJentadueto XR
Authorized genericlinagliptin and metformin
Regular genericlinagliptin and metformin
What you’d pay
Cash price$55a month from the maker
Not soldThere isn’t one
Not soldNone sold yet
Same as Jentadueto XR?
The original
–
–

Brand nameThe maker’s cash price

Boehringer Ingelheim Direct self-pay

Cash price from Boehringer Ingelheim

No insurance $55 a month

Sign up on boehringer-ingelheim.com 

In the maker’s words

“Cash/Self-pay is $55 for a 30-day prescription fill.”

From the maker’s offer on boehringer-ingelheim.com, checked October 23, 2026. Check the maker’s page for who can use it.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s price above. You can usually use one or the other on a fill, not both.

Brand nameTrumpRx.gov price

TrumpRx.gov, the federal government’s drug price site, lists Jentadueto XR at a price its maker agreed to, for people paying without insurance.

From TrumpRx.gov, read October 28, 2026. Its page opens on this price; other strengths and amounts are priced there too. With insurance, check your co-pay first: it may be lower.

Authorized genericNot sold

There isn’t one. An authorized generic is Jentadueto XR itself, from the same company, sold without the brand name, and usually for less. For now Jentadueto XR is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

JENTADUETO XR is a combination of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Limitations of Use

  • Not recommended in patients with type 1 diabetes mellitus
  • Has not been studied in patients with a history of pancreatitis

Source: the FDA label for Jentadueto XR (Boehringer Ingelheim Pharmaceuticals, Inc.), August 19, 2026. Full label on DailyMed 

Good to know